Chief Executive Officer, Xenon Pharmaceuticals
Appears in 1 story
Leading the company through the NDA submission and psychiatry trial pause
Xenon Pharmaceuticals stopped enrolling new patients in its Phase 3 depression and bipolar disorder trials on September 17 after participants reported neuropsychiatric side effects, including a small number of psychosis cases. The company's stock fell more than 25% the next day.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
